These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22693003)

  • 1. Rituximab therapy for Morvan syndrome associated with myasthenia gravis.
    Weiss M
    Muscle Nerve; 2012 Jul; 46(1):139-40. PubMed ID: 22693003
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
    Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
    Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
    Stein B; Bird SJ
    J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab for severe myasthenia gravis--experience from five patients.
    Lindberg C; Bokarewa M
    Acta Neurol Scand; 2010 Oct; 122(4):225-8. PubMed ID: 20199513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review.
    Nelson RP; Pascuzzi RM; Kessler K; Walsh LE; Faught PP; Ramanuja S; Pescovitz MD; Loehrer PJ
    J Clin Neuromuscul Dis; 2009 Jun; 10(4):170-7. PubMed ID: 19494727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis.
    Sun F; Ladha SS; Yang L; Liu Q; Shi SX; Su N; Bomprezzi R; Shi FD
    Muscle Nerve; 2014 Apr; 49(4):487-94. PubMed ID: 23868194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis.
    Sadnicka A; Reilly MM; Mummery C; Brandner S; Hirsch N; Lunn MP
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):230-2. PubMed ID: 20462915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic inflammatory pseudotumor and myasthenia gravis.
    Levin MH; Gopal PP; Galetta SL
    JAMA Ophthalmol; 2014 Mar; 132(3):359-61. PubMed ID: 24626829
    [No Abstract]   [Full Text] [Related]  

  • 9. Rituximab for myasthenia gravis: three case reports and review of the literature.
    Stieglbauer K; Topakian R; Schäffer V; Aichner FT
    J Neurol Sci; 2009 May; 280(1-2):120-2. PubMed ID: 19272616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use and monitoring of low dose rituximab in myasthenia gravis.
    Blum S; Gillis D; Brown H; Boyle R; Henderson R; Heyworth-Smith D; Hogan P; Kubler P; Lander C; Limberg N; Pillans P; Prain K; Staples C; Walsh M; McCombe P; Wong R
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):659-63. PubMed ID: 21071753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab.
    Jonsson DI; Pirskanen R; Piehl F
    Neuromuscul Disord; 2017 Jun; 27(6):565-568. PubMed ID: 28433474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature.
    Koul R; Al Futaisi A; Abdwani R
    Pediatr Neurol; 2012 Sep; 47(3):209-12. PubMed ID: 22883288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report.
    Pillebout E; Rocha F; Fardet L; Rybojad M; Verine J; Glotz D
    Nephrol Dial Transplant; 2011 Jun; 26(6):2044-6. PubMed ID: 21436378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A man in his seventies with prolonged myasthenic crisis.
    Benjaminsen E; Skjeflo GW; Dybwik K; Salvesen R
    Tidsskr Nor Laegeforen; 2012 Oct; 132(19):2182-5. PubMed ID: 23076489
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful rituximab B lymphocyte depletion therapy for angioedema due to acquired C1 inhibitor protein deficiency: association with reduced C1 inhibitor protein autoantibody titers.
    Dreyfus DH; Na CR; Randolph CC; Kearney D; Price C; Podell D
    Isr Med Assoc J; 2014 May; 16(5):315-6. PubMed ID: 24979840
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome.
    Bakshi J; Stevens R
    Lupus; 2013 Jul; 22(8):865-7. PubMed ID: 23740031
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab therapy for chronic periaortitis.
    Maritati F; Corradi D; Versari A; Casali M; Urban ML; Buzio C; Vaglio A
    Ann Rheum Dis; 2012 Jul; 71(7):1262-4. PubMed ID: 22586161
    [No Abstract]   [Full Text] [Related]  

  • 19. [Severe Wegener's granulomatosis successfully treated with rituximab].
    Semenkova EN; Krivosheev OG; Novikov PI; Osipenko VI; Nosova NR; Parfenova SA; Nikiforova NV; Borodin OO
    Ter Arkh; 2010; 82(6):53-5. PubMed ID: 20731113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the management of refractory myasthenia gravis.
    Zebardast N; Patwa HS; Novella SP; Goldstein JM
    Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.